AstraZeneca FY 2025 Results: Revenue and FY 2026 Growth Forecast

Note: This section contains information in English only.
Source: Dukascopy Bank SA
AstraZeneca reported a gross margin of 80% for FY 2025, down 2 points due to profit-sharing on medicines like Lynparza and Enhertu, a $235 million royalty buyout for Saphnelo and rilvegostomig, and US pricing adjustments. Reported operating profit rose 37% to $13.7 billion, while Core operating profit grew 9% to $18.5 billion, reflecting adjustments for intangible asset amortization and impairments. Reported R&D expenses fell 17% to $3.9 billion due to prior-year impairments, while Core R&D increased 4%, driven by accelerated trials and new technologies such as cell therapy and ADCs. Core SG&A expenses rose 3% to support new product launches, and Core net finance expense decreased 7% to $1.1 billion.



Net cash from operations was $14.6 billion, up $2.7 billion from FY 2024, while capital expenditure increased to $3.3 billion to support manufacturing and technology expansion. Net debt declined by $1.2 billion to $23.4 billion, and the dividend was $3.20 per share, with plans to raise it to $3.30 in FY 2026. The company expects mid-to-high single-digit revenue growth, low double-digit Core EPS growth, and a Core tax rate of 18–22% in FY 2026.
Back to articles

Actual Topics

Tue, 10 Feb 2026 12:41:19 GMT

Ferrari 2025 Financial Results: Record Revenues, Strong Margins, and a Bold Electric Future

Ferrari delivered a very strong financial performance in 2025, fueled by a richer product mix and higher personalization, even as it deliberately kept shipment volumes stable to protect exclusivity. Net revenues rose 7% to €7.146 billion, while net profit increased 5% to €1.6 billion. Operating profit grew faster, with EBIT up 12% to €2.11 billion and margins reaching 29.5%. EBITDA

Fri, 06 Feb 2026 10:54:14 GMT

Amazon Delivers Strong 2025 Results on AI-Led Growth

Amazon reported strong results for the fourth quarter and full year 2025, driven by solid growth across its businesses and heavy investment in AI and infrastructure. Q4 net sales rose 14% to $213.4 billion, while net income increased to $21.2 billion, despite special charges. For the full year, sales grew 12% to $716.9 billion and net income climbed to $77.7

Subscribe to "Fundamental Analysis" feed

Souscrire
To learn more about Dukascopy Bank CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.
To learn more about Dukascopy Bank Binary Options / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Dukascopy Bank CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Business Introducer and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.